These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 20643940)

  • 21. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
    Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
    J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glycan Profiles of gp120 Protein Vaccines from Four Major HIV-1 Subtypes Produced from Different Host Cell Lines under Non-GMP or GMP Conditions.
    Wang S; Voronin Y; Zhao P; Ishihara M; Mehta N; Porterfield M; Chen Y; Bartley C; Hu G; Han D; Wells L; Tiemeyer M; Lu S
    J Virol; 2020 Mar; 94(7):. PubMed ID: 31941770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Yeast-elicited cross-reactive antibodies to HIV Env glycans efficiently neutralize virions expressing exclusively high-mannose N-linked glycans.
    Agrawal-Gamse C; Luallen RJ; Liu B; Fu H; Lee FH; Geng Y; Doms RW
    J Virol; 2011 Jan; 85(1):470-80. PubMed ID: 20962094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged.
    Doores KJ; Fulton Z; Huber M; Wilson IA; Burton DR
    J Virol; 2010 Oct; 84(20):10690-9. PubMed ID: 20702629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers.
    Pritchard LK; Vasiljevic S; Ozorowski G; Seabright GE; Cupo A; Ringe R; Kim HJ; Sanders RW; Doores KJ; Burton DR; Wilson IA; Ward AB; Moore JP; Crispin M
    Cell Rep; 2015 Jun; 11(10):1604-13. PubMed ID: 26051934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans.
    Zhang H; Fu H; Luallen RJ; Liu B; Lee FH; Doms RW; Geng Y
    Vaccine; 2015 Sep; 33(39):5140-7. PubMed ID: 26277072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield.
    Pejchal R; Doores KJ; Walker LM; Khayat R; Huang PS; Wang SK; Stanfield RL; Julien JP; Ramos A; Crispin M; Depetris R; Katpally U; Marozsan A; Cupo A; Maloveste S; Liu Y; McBride R; Ito Y; Sanders RW; Ogohara C; Paulson JC; Feizi T; Scanlan CN; Wong CH; Moore JP; Olson WC; Ward AB; Poignard P; Schief WR; Burton DR; Wilson IA
    Science; 2011 Nov; 334(6059):1097-103. PubMed ID: 21998254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.
    Esser MT; Mori T; Mondor I; Sattentau QJ; Dey B; Berger EA; Boyd MR; Lifson JD
    J Virol; 1999 May; 73(5):4360-71. PubMed ID: 10196334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope.
    Hoorelbeke B; Huskens D; Férir G; François KO; Takahashi A; Van Laethem K; Schols D; Tanaka H; Balzarini J
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3287-301. PubMed ID: 20498311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. STD NMR study of the interactions between antibody 2G12 and synthetic oligomannosides that mimic selected branches of gp120 glycans.
    Enríquez-Navas PM; Chiodo F; Marradi M; Angulo J; Penadés S
    Chembiochem; 2012 Jun; 13(9):1357-65. PubMed ID: 22628288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers.
    Go EP; Ding H; Zhang S; Ringe RP; Nicely N; Hua D; Steinbock RT; Golabek M; Alin J; Alam SM; Cupo A; Haynes BF; Kappes JC; Moore JP; Sodroski JG; Desaire H
    J Virol; 2017 May; 91(9):. PubMed ID: 28202756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 N-glycan composition governs a balance between dendritic cell-mediated viral transmission and antigen presentation.
    van Montfort T; Eggink D; Boot M; Tuen M; Hioe CE; Berkhout B; Sanders RW
    J Immunol; 2011 Nov; 187(9):4676-85. PubMed ID: 21957147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The antigenic structure of the HIV gp120 envelope glycoprotein.
    Wyatt R; Kwong PD; Desjardins E; Sweet RW; Robinson J; Hendrickson WA; Sodroski JG
    Nature; 1998 Jun; 393(6686):705-11. PubMed ID: 9641684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human immunodeficiency virus: refolding the envelope.
    Kwong PD
    Nature; 2005 Feb; 433(7028):815-6. PubMed ID: 15729327
    [No Abstract]   [Full Text] [Related]  

  • 35. Identification of the optimal DC-SIGN binding site on human immunodeficiency virus type 1 gp120.
    Hong PW; Nguyen S; Young S; Su SV; Lee B
    J Virol; 2007 Aug; 81(15):8325-36. PubMed ID: 17522223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus.
    Chertova E; Bess JW; Crise BJ; Sowder II RC; Schaden TM; Hilburn JM; Hoxie JA; Benveniste RE; Lifson JD; Henderson LE; Arthur LO
    J Virol; 2002 Jun; 76(11):5315-25. PubMed ID: 11991960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A New Approach to Produce HIV-1 Envelope Trimers: BOTH CLEAVAGE AND PROPER GLYCOSYLATION ARE ESSENTIAL TO GENERATE AUTHENTIC TRIMERS.
    AlSalmi W; Mahalingam M; Ananthaswamy N; Hamlin C; Flores D; Gao G; Rao VB
    J Biol Chem; 2015 Aug; 290(32):19780-95. PubMed ID: 26088135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conserved N-linked oligosaccharides of the C-terminal portion of human immunodeficiency virus type 1 gp120 and viral susceptibility to neutralizing antibodies.
    Hemming A; Gram GJ; Bolmstedt A; Losman B; Hansen JE; Ricksten A; Olofsson S
    Arch Virol; 1996; 141(11):2139-51. PubMed ID: 8973529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition.
    Raska M; Takahashi K; Czernekova L; Zachova K; Hall S; Moldoveanu Z; Elliott MC; Wilson L; Brown R; Jancova D; Barnes S; Vrbkova J; Tomana M; Smith PD; Mestecky J; Renfrow MB; Novak J
    J Biol Chem; 2010 Jul; 285(27):20860-9. PubMed ID: 20439465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization.
    Gray ES; Moore PL; Pantophlet RA; Morris L
    J Virol; 2007 Oct; 81(19):10769-76. PubMed ID: 17634239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.